Скачать или смотреть Biotech Showcase 2012_NeuralStem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. The trial is the first FDA-approved neural stem cell trial to treat ALS and concludes six months after that surgery. Neuralstem's lead cell therapy candidate NSI-566 has been awarded orphan drug designation by the FDA for the treatment of ALS. http://www.neuralstem.com/about-neura...